Literature DB >> 386385

Modulation of immunity by bacillus Calmette-Guérin (BCG).

M S Mitchell, R I Murahata.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 386385     DOI： 10.1016/0163-7258(79)90141-4

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN： 0163-7258            Impact factor:   12.310


× No keyword cloud information.
  9 in total

1.  Morphological aspects of the interaction of Bacillus Calmette-Guérin with urothelial bladder cells in vivo and in vitro: relevance for antitumor activity?

Authors:  J S Teppema; E C de Boer; P A Steerenberg; A P van der Meijden
Journal:  Urol Res       Date:  1992

2.  Natural cell-mediated cytotoxicity in normal human peripheral blood lymphocytes and its in vitro boosting with BCG.

Authors:  R Mandeville; F M Sombo; N Rocheleau
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

3.  Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin.

Authors:  W H De Jong; E C De Boer; A P Van der Meijden; P Vegt; P A Steerenberg; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomised clinical trial.

Authors:  W R Klein; G E Bras; W Misdorp; P A Steerenberg; W H de Jong; R H Tiesjema; A W Kersjes; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

5.  Experimental screening of BCG preparations produced for cancer immunotherapy: safety and immunostimulating and antitumor activity of four consecutively produced batches.

Authors:  W H de Jong; P A Steerenberg; J G Kreeftenberg; R H Tiesjema; W Kruizinga; L M van Noorle Jansen; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

6.  Immunological aspects of intravesical administration of Bacillus Calmette-Guérin (BCG) in the guinea pig.

Authors:  A P van der Meijden; W H de Jong; E C de Boer; P A Steerenberg; F M Debruyne; E J Ruitenberg
Journal:  Urol Res       Date:  1989

7.  Immune reactivity in cattle with ocular squamous cell carcinoma after intralesional BCG immunotherapy.

Authors:  W R Klein; P A Steerenberg; F Poelma; E vd Wiel; V P Rutten; W Misdorp; W H de Jong; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  An anti-neoplastic glycan isolated from Mycobacterium bovis (BCG vaccine).

Authors:  R Wang; M E Klegerman; I Marsden; M Sinnott; M J Groves
Journal:  Biochem J       Date:  1995-11-01       Impact factor: 3.857

Review 9.  Myeloid-derived suppressor cells and vaccination against pathogens.

Authors:  Estefanía Prochetto; Eliana Borgna; Carlos Jiménez-Cortegana; Víctor Sánchez-Margalet; Gabriel Cabrera
Journal:  Front Cell Infect Microbiol       Date:  2022-09-29       Impact factor: 6.073
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.